Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.39 |
| ▸ | NAMPT | P43490 | 2/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16217169 | 0.87 | ESR2 (0.52) | NR1H2ESR2MAPK1MAPTGPR119 | |
| SCHEMBL16217165 | 0.87 | MAPT (0.54) | NR1H2ESR2MAPK1MAPTGPR119 | |
| SCHEMBL24417778 | 0.85 | ESR2 (0.47) | NR1H2HDAC1ESR2MAPK1MAPT | |
| SCHEMBL25862485 | 0.84 | NR1H2 (0.44) | NR1H2HDAC1ESR2MAPK1MAPT | |
| SCHEMBL22403012 | 0.84 | PDK2 (0.50) | NR1H2HDAC1ESR2MAPK1MAPT | |
| SCHEMBL17624333 | 0.83 | HDAC1 (0.42) | HDAC1MAPTNAMPTHDAC2 | |
| SCHEMBL31460333 | 0.82 | HDAC1 (0.41) | NR1H2HDAC1ESR2MAPK1MAPT | |
| SCHEMBL20738563 | 0.82 | HDAC1 (0.41) | NR1H2HDAC1ESR2MAPK1MAPT | |
| SCHEMBL24507069 | 0.82 | HTT (0.43) | NR1H2HDAC1ESR2MAPK1MAPT | |
| SCHEMBL14358443 | 0.81 | HDAC1 (0.40) | NR1H2HDAC1ESR2MAPK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4678634-A1 | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF | Haihe Biopharma Co., Ltd. (CN) | 2026-01-14 | — | — | EP | disclosed |
| EP-4573089-A2 | KRAS INHIBITORS | Bristol-Myers Squibb Company (US) | 2025-06-25 | — | — | EP | disclosed |
| CN-119998275-A | KRAS inhibitors | 百时美施贵宝公司 | 2025-05-13 | — | — | CN | disclosed |
| EP-4486453-A1 | BENZAMIDE COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | F. Hoffmann-La Roche AG (CH) | 2025-01-08 | — | — | EP | disclosed |
| CN-118843616-A | Benzamide compounds for the treatment of bacterial infections | 豪夫迈·罗氏有限公司 | 2024-10-25 | — | — | CN | disclosed |
| WO-2024183793-A1 | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF | 上海海和药物研究开发股份有限公司 | 2024-09-12 | — | — | WO | disclosed |
| US-20240199584-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-06-20 | — | — | US | disclosed |
| WO-2024040109-A2 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-02-22 | — | — | WO | disclosed |
| US-11858939-B2 | Hetero-halo inhibitors of histone deacetylase | ALKERMES, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858939-B2 | Hetero-halo inhibitors of histone deacetylase | ALKERMES, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20210122748-A1 | BICYCLIC INHIBITORS OF HISTONE DEACETYLASE | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2021-04-29 | — | — | US | disclosed |
| US-10919902-B2 | Hetero-halo inhibitors of histone deacetylase | ALKERMES, INC. (US) | 2021-02-16 | — | — | US | disclosed |
| US-20200345700-A1 | LSD1 INHIBITOR AND PREPARATION METHOD AND APPLICATION THEREOF | MEDSHINE DISCOVERY INC. (CN) | 2020-11-05 | — | — | US | disclosed |
| US-10793567-B2 | Bicyclic inhibitors of histone deacetylase | RODIN THERAPEUTICS, INC. (US) | 2020-10-06 | — | — | US | disclosed |
| US-20200282016-A1 | Endoparasitic Depsipeptides | ZOETIS SERVICES LLC | 2020-09-10 | — | — | US | disclosed |
| US-20200247814-A1 | HETERO-HALO INHIBITORS OF HISTONE DEACETYLASE | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2020-08-06 | — | — | US | disclosed |
| WO-2018132533-A1 | BICYCLIC INHIBITORS OF HISTONE DEACETYLASE | RODIN THERAPEUTICS, INC. (US) | 2018-07-19 | — | — | WO | disclosed |
| US-20180194769-A1 | HETERO-HALO INHIBITORS OF HISTONE DEACETYLASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-07-12 | — | — | US | disclosed |
| US-20180194769-A1 | HETERO-HALO INHIBITORS OF HISTONE DEACETYLASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-07-12 | — | — | US | disclosed |
| WO-2017007756-A1 | HETERO-HALO INHIBITORS OF HISTONE DEACETYLASE | RODIN THERAPEUTICS, INC (US) | 2017-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200282016-A1 | Endoparasitic Depsipeptides | VIP, PREP, NGLY1 | NR1H2 2953/4885HDAC1 393/4885ESR2 701/4885 |
| US-11858939-B2 | Hetero-halo inhibitors of histone deacetylase | HDAC2, HDAC1, HDAC6 | NR1H2 357/4885HDAC1 2/4885ESR2 3923/4885 |
| US-20210122748-A1 | BICYCLIC INHIBITORS OF HISTONE DEACETYLASE | HDAC2, HDAC1, HDAC3 | NR1H2 175/4885HDAC1 2/4885ESR2 1989/4885 |
| US-10793567-B2 | Bicyclic inhibitors of histone deacetylase | HDAC2, HDAC1, HDAC11 | NR1H2 227/4885HDAC1 2/4885ESR2 2086/4885 |
| US-20240199584-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | NR1H2 3132/4885HDAC1 2070/4885ESR2 2595/4885 |
| US-20180194769-A1 | HETERO-HALO INHIBITORS OF HISTONE DEACETYLASE | HDAC2, HDAC1, HDAC6 | NR1H2 357/4885HDAC1 2/4885ESR2 3923/4885 |
| US-20200247814-A1 | HETERO-HALO INHIBITORS OF HISTONE DEACETYLASE | HDAC2, HDAC1, HDAC6 | NR1H2 357/4885HDAC1 2/4885ESR2 3923/4885 |
| US-10919902-B2 | Hetero-halo inhibitors of histone deacetylase | HDAC2, HDAC1, HDAC6 | NR1H2 357/4885HDAC1 2/4885ESR2 3923/4885 |
| US-20200345700-A1 | LSD1 INHIBITOR AND PREPARATION METHOD AND APPLICATION THEREOF | KDM1B, KDM1A, KDM2A | NR1H2 216/4885HDAC1 43/4885ESR2 3116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.